United Health Products Inc. – Epic Wound Care Inc. Granted Use of CE Mark on Its HemoStyp™ Trauma Gauze

<0> United Health Products Inc. – Epic Wound Care Inc. Granted Use of CE Mark on Its HemoStyp™ Trauma Gauze </0>

United Health Products, Inc.Dr. Philip Forman CEO646-961-4459

United Health Products, Inc. (OTCQB: UEEC.PK), which develops and markets products and technologies in the healthcare sector, today announced that its hemostatic gauze, which is registered and branded in the U.S.A. under the trademark HemoStyp™, has been granted use of CE mark which is a mandatory conformity mark for products placed on the market in the European Economic Area (EEA) , under the application and registration of its manufacturing agent. UEEC’s CEO Philip Forman stated, “United Health Products is excited to announce that its product labeled under the HemoStyp™ brand is now being provided and manufactured with both CE and FDA marks. We now are exploring several potential opportunities for distribution of the HemoStyp™ gauze within the European Economic Area.” Douglas Beplate COO of Epic Wound Care Inc. acknowledged that a market test of the HemoStyp™ gauze is being negotiated with several European Companies.

About United Health Products, Inc.

United Health Products, Inc. (UEEC) develops, manufactures and markets products and technologies in the healthcare sector. UEEC's operating subsidiary Epic Wound Care, Inc. produces hemostatic gauze, derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudates/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying emerging healthcare products and technologies for strategic partnership or acquisition.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.